Saving lives with breath aerosol diagnostics

The need

• Up to 20% of all primary care consultations are due to respiratory infections¹ ​​​

​​

• They result in 4 million deaths each year, almost all of them due to infections in the lower respiratory tract causing pneumonia²

​​

• Lack of good diagnostic solutions are a main reason for poor outcomes and antibiotic overuse

​​

• Transformative, rapid testing where people first seek care is needed to capture pneumonia early and initiate the right treatment

¹ CDC 2016 National hospital ambulatory medical care survey; Salvi et al. Lancet GH. 3(12):e776 ; OECD 2021. Doctors indicator

² GBD 2019 Diseases and Injuries Collaborators; Vos et al. Lancet 2020. 369(10258): 1204

Our solution 

A non-invasive sample-to-answer breath test that reliably detects multiple lower respiratory tract infections in primary care within minutes in three simple steps:

The impact

• Saving lives by earlier appropriate antibiotic or antiviral treatment and rapid patient referral​

​​

• Reducing healthcare costs: Avelo's rapid test results help to lower the annual costs of USD 52 billion in Europe alone by keeping patients out of the hospital³

​​

• Fighting antimicrobial resistance (AMR): Avelo's test differentiates between viral and bacterial infections to assist in antibiotic stewardship and reduce the > 65% unnecessarily prescribed antibiotics in primary care⁴

​​

• Establishing self-collected breath bioaerosols as a novel diagnostic sample type for new testing solutions

³ European Respiratory Journal (ERJ). European Lung White Book, 2011

⁴ UK Government and Wellcome Trust. The Review on Antimicrobial Resistance (AMR), 2016